| 2019 |
| 01/24 | 651 | 661 | 636 | 649 | -0.31% | 140,800 | 66億2895万 | +9.44% |
| 01/23 | 660 | 668 | 645 | 651 | -2.69% | 71,900 | 66億4937万 | +10.34% |
| 01/22 | 659 | 677 | 643 | 669 | +0.3% | 126,800 | 68億3323万 | +14.16% |
| 01/21 | 700 | 710 | 659 | 667 | -4.44% | 229,600 | 68億1280万 | +14.8% |
| 01/18 | 661 | 700 | 650 | 698 | +4.33% | 269,700 | 71億2944万 | +20.55% |
| 01/17 | 670 | 686 | 657 | 669 | -1.62% | 168,900 | 68億3323万 | +16.35% |
| 01/16 | 650 | 683 | 629 | 680 | +5.1% | 208,200 | 69億4558万 | +18.67% |
| 01/15 | 638 | 664 | 633 | 647 | +3.03% | 196,800 | 66億852万 | +12.91% |
| 01/11 | 629 | 648 | 614 | 628 | +0.8% | 171,700 | 64億1445万 | +9.41% |
| 01/10 | 616 | 629 | 596 | 623 | -0.48% | 199,200 | 63億6338万 | +8.16% |
| 01/09 | 648 | 650 | 619 | 626 | -4.72% | 240,200 | 63億9402万 | +8.3% |
| 01/08 | 627 | 669 | 625 | 657 | +5.8% | 339,500 | 67億1066万 | +13.28% |
| 01/07 | 611 | 642 | 604 | 621 | +3.85% | 459,400 | 63億4295万 | +7.25% |
| 01/04 | 528 | 598 | 526 | 598 | +7.17% | 496,800 | 61億803万 | +3.1% |
| 12/28 | 15:30 取締役異動および人事異動のお知らせ |
| 2018 |
| 12/28 | 495 | 580 | 490 | 558 | +8.98% | 1,008,500 | 56億9946万 | -4.12% |
| 12/27 | 469 | 512 | 463 | 512 | +18.52% | 963,700 | 52億2961万 | -12.33% |
| 12/26 | 15:30 CPN-101(MRX-4TZT)を包含する薬剤と有機溶媒と親油性膏体基剤と粉体を配合した貼付製剤組成物に関する特許(欧州)査定のお知らせ |
| 12/26 | 460 | 477 | 425 | 432 | -3.14% | 510,400 | 44億1249万 | -26.66% |
| 12/25 | 465 | 480 | 433 | 446 | -15.21% | 1,045,100 | 45億5548万 | -25.42% |
| 12/21 | 617 | 618 | 507 | 526 | -13.34% | 2,404,300 | 53億7261万 | -12.91% |
| 12/21 | 8:50 CPN-101(MRX-4TZT)、MRX-1OXTを包含する特許(日本)査定のお知らせ |
| 12/20 | 607 | 607 | 607 | 607 | +19.72% | 102,800 | 61億9995万 | -0.33% |
| 12/20 | 8:50 アルツハイマー治療貼付剤MRX-7MLL治験前相談の結果について |
| 12/19 | 491 | 512 | 482 | 507 | +6.74% | 293,800 | 51億7854万 | -16.75% |
| 12/18 | 503 | 509 | 469 | 475 | -10.55% | 650,500 | 48億5169万 | -22.64% |
| 12/17 | 558 | 564 | 531 | 531 | -5.52% | 145,700 | 54億2368万 | -14.35% |
| 12/14 | 573 | 582 | 558 | 562 | -4.42% | 152,800 | 57億4032万 | -10.22% |
| 12/13 | 569 | 598 | 569 | 588 | +2.8% | 158,900 | 60億589万 | -6.96% |
| 12/12 | 544 | 577 | 542 | 572 | +5.34% | 146,100 | 58億4246万 | -10.06% |
| 12/11 | 565 | 580 | 543 | 543 | -3.21% | 177,200 | 55億4625万 | -15.29% |
| 12/10 | 598 | 598 | 557 | 561 | -6.81% | 306,300 | 57億3011万 | -13.29% |
| 12/07 | 15:00 日本免疫学会学術集会における発表のお知らせ |
| 12/07 | 608 | 616 | 597 | 602 | -0.66% | 162,300 | 61億4888万 | -7.67% |
| 12/06 | 624 | 624 | 602 | 606 | -2.88% | 173,100 | 61億8974万 | -7.34% |
| 12/05 | 644 | 657 | 622 | 624 | -5.88% | 240,400 | 63億7359万 | -5.02% |
| 12/04 | 690 | 702 | 662 | 663 | -4.19% | 161,900 | 67億7194万 | +0.76% |
| 12/03 | 686 | 714 | 675 | 692 | +3.9% | 242,800 | 70億6815万 | +5.49% |
| 11/30 | 15:00 第13回新株予約権(行使価額修正条項付)の取得及び消却完了に関するお知らせ |
| 11/30 | 683 | 691 | 659 | 666 | -3.06% | 152,600 | 68億259万 | +1.83% |
| 11/29 | 658 | 692 | 654 | 687 | +5.05% | 231,100 | 70億1708万 | +5.05% |
| 11/28 | 648 | 673 | 634 | 654 | +2.51% | 133,100 | 66億8002万 | -0.15% |
| 11/27 | 648 | 660 | 637 | 638 | -1.24% | 84,100 | 65億1659万 | -3.04% |
| 11/26 | 637 | 659 | 637 | 646 | +0.31% | 87,200 | 65億9830万 | -2.56% |
| 11/22 | 626 | 646 | 623 | 644 | +3.87% | 101,000 | 65億7788万 | -3.45% |
| 11/21 | 612 | 642 | 607 | 620 | -0.8% | 123,200 | 63億2840万 | -7.74% |
| 11/20 | 643 | 655 | 623 | 625 | -4.29% | 90,700 | 63億7943万 | -7.95% |
| 11/19 | 619 | 660 | 619 | 653 | +5.66% | 140,800 | 66億6523万 | -4.53% |
| 11/16 | 638 | 661 | 615 | 618 | -3.13% | 159,400 | 63億798万 | -10.17% |
| 11/15 | 613 | 644 | 611 | 638 | +3.91% | 125,600 | 65億1212万 | -7.94% |
| 11/14 | 632 | 634 | 609 | 614 | -1.92% | 135,200 | 62億6715万 | -11.78% |
| 11/13 | 600 | 636 | 590 | 626 | +0.81% | 279,400 | 63億8964万 | -10.95% |
| 11/12 | 652 | 660 | 615 | 621 | -10.26% | 575,100 | 63億3860万 | -12.41% |
| 11/09 | 15:00 第13回新株予約権(行使価額修正条項付)の取得及び消却に関するお知らせ |
| 11/09 | 15:00 平成30年12月期連結業績予想の修正に関するお知らせ |
| 11/09 | 15:00 平成30年12月期第3四半期決算短信〔日本基準〕(連結) |
| 11/09 | 688 | 710 | 687 | 692 | -1.14% | 226,400 | 70億6331万 | -3.35% |
| 11/08 | 703 | 725 | 700 | 700 | 0% | 274,500 | 71億4497万 | -2.91% |
| 11/07 | 680 | 713 | 670 | 700 | +2.94% | 199,000 | 71億4497万 | -3.58% |
| 11/06 | 703 | 712 | 675 | 680 | -3.27% | 150,200 | 69億4082万 | -7.1% |
| 11/05 | 670 | 720 | 670 | 703 | +2.18% | 147,900 | 71億7559万 | -5.13% |
| 11/02 | 662 | 689 | 662 | 688 | +4.4% | 154,200 | 70億2248万 | -8.14% |
| 11/01 | 15:00 第三者割当による第13回新株予約権(行使価額修正条項付)の月間行使状況に関するお知らせ |
| 11/01 | 670 | 674 | 652 | 659 | -2.08% | 106,700 | 67億2647万 | -13.06% |
| 10/31 | 658 | 675 | 646 | 673 | +3.38% | 145,700 | 68億6937万 | -12.37% |
| 10/30 | 606 | 654 | 601 | 651 | +5.51% | 246,400 | 66億4482万 | -16.11% |
| 10/29 | 641 | 660 | 613 | 617 | -3.59% | 261,500 | 62億9778万 | -21.6% |
| 10/26 | 669 | 681 | 618 | 640 | -2.44% | 363,500 | 65億3254万 | -19.9% |
| 10/25 | 680 | 687 | 652 | 656 | -7.87% | 392,200 | 66億9585万 | -19.21% |
| 10/24 | 730 | 738 | 695 | 712 | -1.93% | 315,700 | 72億6745万 | -13.7% |
| 10/23 | 763 | 763 | 722 | 726 | -4.97% | 229,600 | 74億1035万 | -13.05% |
| 10/22 | 750 | 772 | 740 | 764 | +2.14% | 132,000 | 77億9822万 | -9.48% |
| 10/19 | 768 | 768 | 735 | 748 | -3.48% | 146,400 | 76億3491万 | -12.1% |
| 10/18 | 778 | 800 | 771 | 775 | -1.52% | 132,700 | 79億1050万 | -10.2% |
| 10/17 | 776 | 805 | 767 | 787 | +2.34% | 234,000 | 80億3298万 | -9.75% |
| 10/16 | 730 | 773 | 729 | 769 | +5.05% | 176,600 | 78億4925万 | -12.61% |
| 10/15 | 746 | 750 | 725 | 732 | -2.66% | 150,600 | 74億7159万 | -17.57% |
| 10/12 | 728 | 757 | 718 | 752 | +4.44% | 190,700 | 76億7573万 | -16.44% |
| 10/11 | 719 | 745 | 699 | 720 | -7.69% | 629,100 | 73億4911万 | -21.14% |
| 10/10 | 778 | 797 | 748 | 780 | +0.52% | 234,600 | 79億6153万 | -15.31% |
| 10/09 | 784 | 792 | 764 | 776 | -1.9% | 286,400 | 79億2070万 | -16.29% |
| 10/05 | 801 | 824 | 791 | 791 | -2.83% | 276,700 | 80億7381万 | -15.49% |
| 10/04 | 829 | 847 | 804 | 814 | -1.93% | 260,500 | 83億857万 | -13.77% |
| 10/03 | 857 | 865 | 791 | 830 | -3.49% | 432,400 | 84億7189万 | -13% |
| 10/02 | 901 | 904 | 853 | 860 | -4.34% | 409,300 | 87億7810万 | -10.23% |
| 10/01 | 15:00 第三者割当による第13回新株予約権(行使価額修正条項付)の月間行使状況に関するお知らせ |
| 10/01 | 898 | 905 | 884 | 899 | -1.53% | 184,300 | 91億7618万 | -5.77% |
| 09/28 | 896 | 913 | 875 | 913 | +1.78% | 260,000 | 93億1908万 | -3.69% |
| 09/27 | 906 | 919 | 890 | 897 | -1.86% | 286,900 | 91億5576万 | -4.57% |
| 09/26 | 901 | 926 | 895 | 914 | +3.16% | 296,300 | 93億2928万 | -1.93% |
| 09/25 | 910 | 910 | 866 | 886 | -2.74% | 485,700 | 90億4349万 | -4.01% |
| 09/21 | 936 | 939 | 905 | 911 | -2.04% | 560,800 | 92億9866万 | -0.65% |
| 09/20 | 952 | 965 | 915 | 930 | -1.9% | 821,600 | 94億9074万 | +2.42% |
| 09/19 | 957 | 974 | 942 | 948 | -3.56% | 489,000 | 96億7443万 | +5.57% |
| 09/18 | 953 | 998 | 936 | 983 | +1.87% | 497,800 | 100億3161万 | +10.57% |
| 09/14 | 955 | 979 | 926 | 965 | +2.12% | 405,400 | 98億4792万 | +9.91% |
| 09/13 | 957 | 970 | 921 | 945 | -1.66% | 629,000 | 96億4381万 | +8.87% |
| 09/12 | 1,037 | 1,057 | 930 | 961 | -7.77% | 1,221,200 | 98億710万 | +11.87% |
| 09/11 | 999 | 1,044 | 995 | 1,042 | +4.93% | 751,400 | 106億3371万 | +22.73% |
| 09/10 | 992 | 1,038 | 974 | 993 | +0.51% | 785,000 | 101億3366万 | +18.78% |
| 09/07 | 970 | 1,007 | 955 | 988 | +0.71% | 695,200 | 100億8263万 | +19.9% |
| 09/06 | 997 | 1,038 | 961 | 981 | -3.54% | 1,232,400 | 100億1120万 | +20.37% |
| 09/05 | 1,045 | 1,090 | 1,002 | 1,017 | -5.04% | 2,138,400 | 103億7858万 | +26.18% |
| 09/04 | 956 | 1,080 | 936 | 1,071 | +15.16% | 3,730,900 | 109億2966万 | +34.55% |
| 09/03 | 15:00 第三者割当による第13回新株予約権(行使価額修正条項付)の月間行使状況に関するお知らせ |
| 09/03 | 15:00 日本癌学会学術総会における発表のお知らせ |
| 09/03 | 923 | 954 | 904 | 930 | +1.2% | 761,000 | 94億9074万 | +18.62% |
| 08/31 | 971 | 993 | 906 | 919 | -9.19% | 1,557,200 | 93億7848万 | +18.28% |
| 08/30 | 997 | 1,035 | 964 | 1,012 | +1.2% | 1,985,500 | 103億2756万 | +30.92% |
| 08/29 | 1,155 | 1,167 | 992 | 1,000 | -6.1% | 7,023,000 | 102億510万 | +31.06% |
| 08/28 | 1,065 | 1,065 | 1,065 | 1,065 | +16.39% | 57,400 | 108億6843万 | +41.06% |
| 08/27 | 915 | 915 | 915 | 915 | +19.61% | 22,200 | 93億3766万 | +23.15% |
| 08/27 | 8:30 武田薬品工業との技術ライセンス契約締結のお知らせ |
| 08/24 | 759 | 778 | 744 | 765 | +2.82% | 161,400 | 78億690万 | +3.66% |
